Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. Summary
       SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

 SummaryChartsNewsRatingsCompany 
Company
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates... 
More about the company
Ratings of Biovica International AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BIOVICA INTERNATIONAL AB (PUBL)
06/30BIOVICA INTERNATIONAL AB : – Annual report for the financial year 2020/202..
AQ
06/17BIOVICA INTERNATIONAL : Year-end Report February-April 2020/2021
AQ
06/17Biovica International AB Publ Reports Earnings Results for the Fourth Quarter..
CI
06/11BIOVICA INTERNATIONAL : - Premium potential
AQ
05/22BIOVICA INTERNATIONAL : Capital Markets Day invitation June 9
AQ
05/20BIOVICA INTERNATIONAL : DiviTumTKa shows strong capabilities in malignant melano..
AQ
05/20Biovica’S Divitumtka Shows Strong Capabilities in Malignant Melanoma
CI
04/29BIOVICA INTERNATIONAL : strengthens the management team
AQ
04/29Biovica Announces Management Appointments
CI
04/23BIOVICA INTERNATIONAL : DiviTum®TKa budget impact model results show potential f..
AQ
03/18BIOVICA INTERNATIONAL : Q3 Interim report November-January 2020/2021
AQ
03/11BIOVICA INTERNATIONAL : DiviTumTKa prognostic for long-term outcome
AQ
03/02Biovica International AB Publ Reports Earnings Results for the Third Quarter ..
CI
02/26BIOVICA INTERNATIONAL : Nomination Committee for Biovica for the 2021 Annual Gen..
AQ
01/29BIOVICA INTERNATIONAL : FDA resumes review of DiviTum®TKa submission
AQ
More news
News in other languages on BIOVICA INTERNATIONAL AB (PUBL)

- No features available -

More news
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | SE0008613731 | MarketScreener
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors